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Involvement of gelsolin in TGF-beta 1
induced epithelial to mesenchymal
transition in breast cancer cells
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Abstract
Background: Increasing evidence suggests that transforming growth factor-beta 1 (TGF-β1) triggers epithelial to
mesenchymal transition (EMT) and facilitates breast cancer stem cell differentiation. Gelsolin (GSN) is a ubiquitous
actin filament-severing protein. However, the relationship between the expression level of GSN and the TGF-β
signaling for EMT progression in breast cancer cells is not clear.
Results: TGF-β1 acted on MDA-MB231 breast cancer cells by decreasing cell proliferation, changing cell morphology
to a fibroblast-like shape, increasing expressions for CD44 and GSN, and increasing EMT expression and cell migration/
invasion. Study with GSN overexpression (GSN op) in both MDA-MB231 and MCF-7 cells demonstrated that increased
GSN expression resulted in alterations of cell proliferation and cell cycle progression, modification of the actin filament
assembly associated with altering cell surface elasticity and cell detachment in these breast cancer cells. In addition,
increased cell migration was found in GSN op MDA-MB231 cells. Studies with GSN op and silencing by small
interfering RNA verified that GSN could modulate the expression of vimentin. Sorted by flow cytometry, TGF-β1
increased subpopulation of CD44+/CD22- cells increasing their expressions for GSN, Nanog, Sox2, Oct4, N-cadherin,
and vimentin but decreasing the E-cadherin expression. Methylation specific PCR analysis revealed that TGF-β1
decreased 50 % methylation but increased 3-fold unmethylation on the GSN promoter in CD44+/CD22- cells. Two
DNA methyltransferases, DNMT1and DNMT3B were also inhibited by TGF-β1.
Conclusions: TGF-β1 induced epigenetic modification of GSN could alter the EMT process in breast cancer cells.
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Background
TGF-β1 is a secreted cytokine involved in controlling
gene expression and ultimately cell cycle and tissue re-
pair [1]. In the initial stage of tumorigenesis, TGF-β1
acts as a tumor suppressor [2]. With tumor progression
cancer cells overproducing TGF-β1 turn to promote
cancer cell proliferation, invasion and metastasis, hence
become resistant to the TGF-β1-induced growth inhib-
ition in their later stage [2]. In addition, the TGF-β1 sig-
naling pathway has been shown to cause a constitutive
epithelial to mesenchymal transition (EMT) facilitating a
highly invasive and metastatic phenotype in breast tu-
mors [3, 4]. Recent evidence also demonstrated that
TGF-β could increase breast tumor-initiating cell num-
bers in the low claudin expression subtype of breast tu-
mors [5]. Apparently, the TGF-β signaling for EMT, cell
motility, and invasiveness might play an important role
in enriching the cancer stem cell (CSC) pool in breast
tumors [6].
The actin cytoskeleton underlies several cellular func-
tions including cell differentiation in both normal and
tumor cells [7–10]. It has been shown that the TGF-β sig-
naling via Smad and p38MAPK caused upregulation of
actin binding proteins, including tropomyosin, α-actinin,
and calponin, to control the stress fiber formation, which
might contribute to modulation of cell motility and inva-
sive phenotype with EMT in tumor cells [11, 12]. Gelsolin
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(GSN), one of the most potent members of the actin-
severing superfamily, plays a key role in the regulation of
actin filament assembly and disassembly [13, 14]. GSN in-
volves in many cellular properties for carcinogenesis phe-
notypes, EMT, motility, apoptosis, proliferation, and
differentiation [15–17]. However, it remains to be deter-
mined if the TGF-β signaling events also include the
modulation of GSN expression for promotion of breast
cancer cell differentiation.
Similar to leukemia, several CSC-like subpopulations
have been thought to exist in breast cancers [18, 19].
These breast CSCs acquire the ability to differentiate into
all the different cells found within a tumor that become
chemotherapy resistant [20, 21]. In this study, the TGF-
β1-induced MDA-MB231breast cancer cells as a model
for CSC differentiation were used to investigate whether
the expression level of GSN is regulated by the TGF-β1
signaling for promoting breast CSC differentiation. Results
reported here suggest that GSN involves in the TGF-β1-
driving CSC differentiation by the process of EMT in
breast cancer cells.
Methods
Cell culture and TGF-β1 treatment
MCF-7 cells in Dulbecco’s modified essential medium
(DMEM, Gibco) containing glutamine, while MDA-
MB231 in DMEM containing sodium bicarbonate, both
supplemented with antibiotics and 10 % fetal bovine
serum (FBS) were cultured in a 5 % CO2 incubator at
37 °C. To determine the growth inhibition, 5000 cells for
each cell line were plated in 96-well plates with or with-
out TGF-β1 treatment. Cell viability and proliferation
was measured using the MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] assay (ATCC,
Manassas, VA, USA) [22, 23].
Cell migration and invasion assay
The invasion and migration assay of cancer cells were
performed using modified Boyden chamber assay with
a FalconTM Cell Culture Insert (BD Biosciences). To
create an invasion assay the membrane was coated
with a Matrigel to simulate the typical matrices that
cancer cells encounter during the invasion process in
vivo. In contrast, the membrane without coating was
used only for the migration assay. In both measure-
ments, the cells (105 cells/ml) were placed on upper
side and a chemoattractant (10 % FBS) on the lower
side. Cells that migrated through the membrane were
fixed with 100 % absolute alcohol, stained with crystal
violet. After air dried, migrated cells were then added
with 30 % acetic acid, and quantitated by measuring
the optical density at 590 nm in a micro-plate reader.
Cell cycle phase determination
Cells (107) were seeded in a 10-cm dish in DMEM-0.2 %
FBS and cultured in a CO2 incubator at 37 °C for 24 h.
The cells were then changed to fresh medium, trypsinized,
and centrifuged. The pellet was washed and re-suspended
in 1 ml of pre-chilled phosphate buffer solution (PBS) and
the cells fixed by gradually adding 3 ml of 95 % ethanol,
then were stored in a deep freezer (−20 °C) overnight. The
cells were then washed three times by centrifugation and
resuspension in pre-chilled PBS. To stain the cells with
propidium iodide (PI), the cells were resuspended in PBS
containing 0.1 % Triton X-100, 20 μg/ml of PI, and
0.2 mg/ml of RNase A and incubated for 30 min at room
temperature in the dark. Samples were analyzed on a flow
cytometer (FC500 Flow Cytometry System, Beckman
Coulter, Inc.) with a 488 nm excitation laser. The cell cycle
phases were determined using the computerized software
provided with the machine (CXP Software, Beckman
Coulter, Inc.).
Cell staining for FACS flow cytometry
Cells (107) were incubated with fluorochrome-conjugated
antibodies followed by fluorescence-activated cell sorting
(FACS). To characterize stem cell markers in breast cancer
cells, the following antibodies were used: allophycocyanin
(APC)-conjugated anti-human CD44 (clone G44-26,
mouse IgG2b, BD Pharmingen, CA, USA), phycoerythrin
(PE)-conjugated anti-human CD24 (clone ML5, mouse
IgG2a, BD Pharmingen, CA, USA). Single-cell suspensions
dissociated from the dishes, using cell dissociation buffer
(GIBCO), were stained with flurochrome antibody for
30 min at 4 °C and analyzed by a flow cytometry of BD
FACS Aria apparatus (BD Biosciences, Palo Alto, CA).
RNA extraction, semi-quantitative RT-PCR, real-time qPCR,
comparative CT method for quantification of mRNA
expression
The procedures for RNA extraction, semi-quantitative
reverse transcription polymerization chain reaction (semi-
quantitative RT-PCR), and qPCR were described previ-
ously [22–24]. SYBR Green dye was used as a real-time re-
porter of the presence of double-stranded DNA. The
following primers specific for stem cell markers (i.e. Oct4,
Sox2 and Nanog), for EMT markers (i.e. N-cadherin, and
vimentin, and E-cadherin), for GSN, and for DNMT1/
DNMT3B were synthesized: Oct4, forward 5′-CCTGAAG
CAGAAGAGGATCA-3′ and reverse 5′-CCGCAGCTT
ACACATGTTCT-3′; Sox2, forward 5′-CGATGCCGACA
AGAAAACTT -3′ and reverse 5′-CAAACTTCCTGCAA
AGCTCC-3′; Nanog, forward 5′-TTCAGTCTGGACAC
TGGCTG-3′ and reverse 5′-CTCGCTGATTAGGCTC
CAAC-3′; E-cadherin, forward 5′-GCCTCCTGAAAAGA
GAGTGGAAG-3′ and reverse 5′-TGGCAGTGTCTCTC
CAAATCCG-3′; N-cadherin, forward 5′-ACAGTGGCC
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ACCTACAAAGG-3′ and reverse 5′-CCGAGATGGGGT
TGATAATG-3′; Vimentin, forward 5′-AGGAAATGGCT
CGTCACCTTCGTGAATA-3′ and reverse 5′-GGAGTG
TCGGTTGTTAAGAACTAGAGCT-3′; GSN, forward
5′-ACGGACCCAGCCAATCG-3′ and reverse 5′-CATC
ATCCCAGCCAAGGAA-3′; DNMT1, forward 5′-AAGA
CAAAGACCAGGATGAGAAG-3′ and reverse 5′-GGGT
GTTGGTTCTTTGGTTTG-3′; DNMT3B, forward 5′-C
CATTCGAGTCCTGTCATTG-3′ and reverse 5′-GCAA
TGGACTCCTCACACAC-3′. The primers for actin bind-
ing proteins were: Tropomyosin 1 (Tm1), forward 5′-TC
ATCATTGAGAGCGACCTG-3′ and reverse 5′-CTTGT
CGGAAAGGACCTTGA-3′; Caldesmon, forward 5′-CT
GGCTTGAAGGTAGGGGTTT -3′ and reverse 5′-TTG
GGAGCAGGTGACTTGTTT-3′; Profilin, forward 5′-CT
GTCAGGACGCGGCCATCG-3′ and reverse 5′-AACGT
TTTCCCGGGGACGGC-3′. GAPDH, an internal control,
had the forward primer 5′-ATGGGGAAGGTGAAGGTC
G-3′ and the reverse primer 5′-TAAAAGCAGCCCTGG
TGACC-3′, respectively.
Immunoblotting
Protein contents of total cell lysates from TGF-β1 treated
or untreated cells were analyzed by western blot. Samples
with same amounts of protein were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, then
the proteins were electro-transferred onto polyvinylidene
difluoride membranes. The primary antibodies used were:
mouse monoclonal anti-human GSN (Sigma GS-2C4;
1:10000 dilution), mouse monoclonal anti-human CD44
(Abcam;1:1000 dilution), mouse monoclonal anti-human
E-cadherin (2Q663) (sc-71008), human-β-catenin (9 F2)
(sc-47752), human GSK-3β (H-76) (sc-9166), human cyc-
lin D1 (DSC-6) (sc-20044), mouse monoclonal anti-
human N-cadherin (H-63) (sc-7939) (all from Santa Cruz;
1: 2000 dilution), mouse monoclonal anti-β-actin (Sigma,
1: 10000 dilution), rabbit monoclonal anti-Tm1 (Sigma,
1:2000 dilution), rabbit monoclonal anti-caldesmon (Santa
Cruz, 1:5000 dilution), rabbit monoclonal anti-profilin
(Santa Cruz, 1:3000 dilution), rabbit monoclonal anti-
human vimentin (Abcam; 1:1000 dilution), and rabbit
polyclonal anti-GAPDH (GeneTex GTX100118; 1:5000).
The secondary antibodies used (1:5000 dilution) were goat
anti-rabbit IgG (Sigma), and goat anti-mouse IgG (Sigma).
GSN overexpression and silencing by small interfering
RNA (siRNA)
The pc6-GSN plasmid construct was cotransfected with
GSN into both MCF-7 and MDA-MB231 breast cancer
cells using lipofectamine 2000 (Invitrogen). The full-
length cytoplasmic GSN cDNA [24, 25] was cloned into
the expression vector pcDNA6-V5/His. Before transfec-
tion, cells were cultured in a 6-well plate containing cul-
ture medium without antibiotics at a density of 70-80 %
confluence. Both the lipofectamine and DNA constructs
were diluted with transfection medium without serum
and incubated for 5 min. Subsequently, the diluted DNA
constructs and diluted lipofectamine were mixed at a
1:2.5 ratio of DNA to lipofectamine. After gentle shaking
and incubation for 20 min, the DNA-lipofectamine com-
plexes were added to each well and incubated in a CO2
incubator at 37 °C for 6 h. The culture medium was re-
placed with serum-containing DMEM.
Sixty to eighty percent confluent cells were trans-
fected with siRNAs directed to human GSN (sc-7330),
according to the manufacturer’s guidelines (Santa Cruz
Biotechnology). The cells received 10 μM siRNA were
incubated for 6 h at 37 ° C in a CO2 incubator. At 24
and 48 h after transfection total RNA were extracted
for reverse transcription and qPCR measurements to
confirm downregulation of GSN expression [22, 24].
Atomic force microscopy
DI-Dimension 3100 AFM (Digital Instruments, Santa Bar-
bara, CA) was applied to obtain cell surface contour im-
ages in contact mode and measure the interfacial forces in
tapping mode [24]. The V-shaped silicon cantilevers with
a spring constant of ~0.9 to 0.12 N/m were used for im-
aging cell surface areas (20 × 20 μm) in phosphate buffer.
Approximately 10–20 spots of this scanning region were
randomly selected using the same probe to extend for-
ward 1 nm deep and to retract back to the starting point.
The retracting force-distance curves were used to calcu-
late the adhesion forces that correspond to the elasticity of
cell membrane surface.
Cell detachment measurements
Cells (105) plated on a 12-well plate were treated with
150 μl of TrypLETM (Invitrogen) for 60, 90, and 180 s,
respectively, followed by adding 1 ml of cell culture
medium to stop the action of trypsin. Detached cells
post treatments with TrypLETM for 60, 90, and 180 s
were collected and measured the cell number by trypan
blue exclusion assay. The detached cell numbers for the
group with 180 s post trypsin treatment were used to
normalize the degree of cell detachment for the group
with 60 or 90 s after trypsin treatments.
Methylation-specific PCR analyses
Methylation status of GSN was determined by
methylation-specific PCR (MSPCR) using bisulphate-
modified genomic DNA as the template. Genomic DNA
was treated with bisulphate by using the Zymo DNA
Modification Kit (Zymo Rearch, Orange, CA, USA) ac-
cording the protocol provided by the manufacturer.
Methylation-specific GSN primers are: forward: 5’-ATGT
TTATTTGATAAACGAGGGAAAC-3’, and reverse: 5’-C
ATTAAACAAACGCCTCGAA-3’; and unmethylation-
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specific GSN primers: forward: 5’-GTTTATTTGATAAAT
GAGGAAATGG-3’ and reverse: 5’-TAAACCATTAAAC
ACCTCAAA-3’.
Statistical analysis
Quantitative values are presented as the mean and
standard error of the mean (mean ± SEM). A difference
was considered to be statistically significant when the P
value was less than 0.05.
Results
Effects of TGF-β1 treatment on cell proliferation, the
expression of CD44, GSN, and EMT markers (i.e. N-cadherin,
vimentin, and E-cadherin) in MDA-MB231 breast cancer cells
To test the appropriate condition for TGF-β1 induction,
MDA-MB231 breast cancer cells were treated with TGF-β1
from 1 to 20 ng/ml for 0, 24, 48, 72, and 96 h. Treatment
with > 1 ng/ml TGF-β1 for 72 h sufficiently decreased cell
proliferation (Fig. 1a) in MDA-MB231 cells. Applying dif-
ferent concentrations (1, 2, 5, 10, 20 ng/ml) of TGF-β1 to
cells in culture medium for 3 days, MDA-MB231 cells
showed a dose dependent increase in protein expressions
for CD44 and GSN (Fig. 1b). In addition, MDA-MB231
cells treated with TGF-β1 from 1 to 5 ng/ml for 3 days also
increased the expression of mesenchymal cell markers (i. e.
N-cadherin, vimentin) but decreased the expression for epi-
thelial cell marker (i.e. E-cadherin) (Fig. 1c). In parallel, the
mRNA level was increased for GSN and N-cadherin
and vimentin but decreased for E-cadherin in MDA-
MB231 cells treated with 2 ng/ml TGF-β1 for 3 days, as
compared to control without TGF-β1 (Fig. 1d). In
addition, the TGF-β1 treatment was confirmed to facili-
tate cell migration and invasion in MDA-MB231 breast
cancer cells.
Fig. 1 Effects of TGF-β1 treatment on cell proliferation, the expression of CD44, GSN, and EMT markers (i.e. N-cadherin, vimentin, and E-cadherin)
in MDA-MB231 breast cancer cells. a MTT assay of cell viability after incubation of MDA-MB231 breast cancer cells with TGF-β1 from 1 to 5 ng/ml
for 0, 24, 48, 72, and 96 h. b Western blotting (top) with quantitative analyses (bottom) showed a dose dependent increase in protein expressions
for CD44 and GSN in MDA-MB231 cells treated with 0, 1, 2, 5, 10, 20 ng/ml of TGF-β1 for 72 h. c Western blotting (top) with quantitative analyses
(bottom) of vimentin, N-cadherin, CD44, and E-cadherin levels in MDA-MB231cells treated with 0, 1, 2, 5 ng/ml of TGF-β1 for 72 h. GAPDH used
as an internal control. d Real-time quantitative PCR (qPCR) analysis showed the mRNA level for GSN, E-cadherin, N-cadherin, and vimentin in
MDA-MB231 cells treated with or without 2 ng/ml TGF-β1 for 3 days. In a, b, c, and d, the values are the mean ± SEM (n = 6), with * indicating a
significant difference compared to the untreated cells
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Effects of GSN op on cell proliferation, cell cycle
progression, and the expression of GSK-3β, β-catenine, and
cyclin D1 in MDA-MB231 and MCF-7 breast cancer cells
To further determine the functional role of increased
GSN expression in the TGF-β induced signaling for
modulation of breast cancer cell progression, we con-
ducted GSN overexpression (GSN op) in the two human
breast cancer cell lines of MDA-MB231 and MCF-7.
Stable clones of GSN op cells have 2- to 6- folds of
GSN overexpression and the longer doubling time for
cell proliferation in both MDA-MB231 and MCF-7
cells (Fig. 2a and c). This is consistent with the find-
ing that TGF-β1 treatment decreased cell proliferation
(Fig. 1a) with increased GSN expression (Fig. 1b and
d) in MDA-MB231 cells. Flow cytometry also revealed
that cell cycle progression arrest at G0/G1 phase ac-
companying by halting cell cycle progression to DNA
synthesis (S phase) occurred in GSN op MDA-MB231
and GSN op MCF-7 cells as compared to their con-
trols, respectively (Fig. 2b and d).
Glycogen synthase kinase-3β (GSK-3β) is a key compo-
nent of multiple signaling pathways involved in the regula-
tion of cell fate, protein synthesis, glycogen metabolism,
cell mobility, proliferation, and survival [26–28]. By pre-
venting cells from entering the cell cycle, GSK-3β par-
ticipates in the regulation of the β-catenin signaling
pathway by modulating cyclin D1 expression levels
[29]. As compared to control cells, the expression
levels of GSK-3β was also increased in concomitant
with the decrease of the levels of cyclin D1 and β-
catenin in GSN op MDA-MB231 and GSN op MCF-7
cells, which may cause the subsequent cell cycle arrest
at the G1-S phase and hence halting DNA synthesis in
those cells (Fig. 2e).
Effects of GSN op on changes of cell morphology, cell
surface elasticity, cytoskeletal protein expression, cell
detachment, and migration in MDA-MB231 breast cancer
cells
In comparison with control MDA-MB 231 cells (Ctr),
several GSN op clones of MDA-MB231 cells were found
to alter morphological changes in cell shapes (Fig. 3a)
with increased cell surface elasticity (Fig. 3b). Cell sur-
face elasticity was determined by measuring adhesion
force in the control and GSN op MDA-MB 231 cells
(Fig. 3b). The adhesion force measured on the cell sur-
face was 2.66 ± 0.10 and 3.30 ± 0.13 nN for the control
and GSN op cells, respectively (Fig. 3b). Clearly, the up-
regulation of GSN could alter the cell surface adhesion
associated with morphological modification in breast
cancer cells. Since the dynamic formation of cell surface
adhesion and detachment is required for cancer cell mo-
tility and invasion [30], we also determined the effect of
GSN op on the cell detachment in breast cancer cells
(Fig. 3c). Result obtained showed that cell detachment
from extracellular matrix was increased for GSN op cells
as compared to control cells (Fig. 3c). This suggested
that GSN severing the actin filament might contribute to
offset the cell adhesion and or detachment to extra-
cellular matrices in breast cancer cells. Interestingly,
GSN op MDA-MB231 cells were also found to increase
the protein content for Tropomyosin 1 (Tm1) as com-
pared to controls (Fig. 3d). This is consistent with our
previous finding that both GSN and Tm1 could affect
the cell surface adhesion and cell proliferation in breast
cancer cells [22]. To determine the effect of increased
Tm1 expression levels on the cell detachment in GSN
op MDA-MB231cells, siTm1 was conducted in the con-
trol and GSN op cells, respectively (Fig. 3e). Gene silen-
cing Tm1 caused to decrease the cell detachment in
both control and GSN op MDA-MB231 cells (Fig. 3e),
suggesting that upregulation of Tm 1 by GSN op might
contribute to facilitate cell detachment in MDA-MB231
cells. To verify that increases in GSN severing the actin
filament caused to enhance cell motility in breast can-
cer cells, cell migration assay was compared in control
and GSN op MDA-MB 231 cells (Fig. 3f ). The result
showed that GSN op significantly enhanced cell migra-
tion (~9 fold) in MDA-MB231 cells (Fig. 3e). This is
consistent with the previous finding that down-
regulation of GSN family proteins in MDA-MB 231
cells reduced the invasive and motile properties of
breast cancer cells [31].
Effects of GSN op and/or silencing by small interfering
RNA on the expression of vimentin
To confirm that GSN plays a crucial role in the TGF-β1
induced EMT in breast cancer cells, studies with GSN
op and/or siGSN were conducted in MDA-MB231 cells
for measuring their effects on the expression levels of
mesenchymal cell marker, vimentin (Fig. 4). Western
analysis showed that in GSN op MDA-MB231 cells GSN
op significantly increased the protein content of vimen-
tin as compared to control cells without GSN op
(Fig. 4a). The increase in the protein content of GSN
and vimentin returned to the control level with siRNA
treatment on GSN op cells (Top panel of Fig. 4a). In
contrast, MDA-MB231 cells treated with siGSN caused
decreases in the protein contents of vimentin and GSN
by ~86 % and ~42 %, respectively (Fig. 4b).
TGF-β1 induction increases the CD44+/CD24- subpopulation
by coordinating gene expressions for CSC markers, EMT
markers, and GSN in MDA-MB231 cells
To characterize CSC-like phenotypes in TGF-β1 treated
cells, fluorescence-activated cell sorting (FACS) flow
cytometry was used to isolate subpopulation of CD44
+/CD24- for MDA-MB-231 cells. Under the condition
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Fig. 2 Effects of GSN op on cell proliferation, cell cycle progression, and the expression of GSK-3β, β-catenine, and cyclin D1 in MDA-MB231
and MCF-7 breast cancer cells. GSN overexpression increased the doubling time for cell proliferation in stable GSN-overexpressing (GSN op)
clones of (a) MDA-MB231, and (c) MCF-7 breast cancer cells as compared to their controls (Ctr), respectively. Flow cytometry determined the
cell population at different cell cycle phases: G0/G1, S, and G2 in control and GSN op cells of (b) MDA-MB231, and (d) MCF-7 cells, respectively.
e GSN overexpression altered the protein levels and mRNA expression of GSK-3β, β-catenin, cyclin D1 in MDA-MB231 or MCF-7 cells. β-actin
used as an internal control. In a, b, c, d and e, the values are the mean ± SEM (n = 6), with * indicating a significant difference compared to
the cells in control and GSN op, respectively
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of 2 ng/ml TGF-β1 for 3 days, the population of CD44
+/CD24- MDA-MB231 breast cancer cells were in-
creased (Fig. 5a). After collection by FACS flow cytom-
etry, these cells were found to increase the gene
markers for stem cell pluripotency (i.e. Oct4, Sox2 and
Nanog) (Fig. 5b), the gene expression for mesenchymal
cell markers such as N-cadherin, and vimentin, but to
decrease in the gene expression for epithelial cell
marker such as E-cadherin (Fig. 5c). This result indi-
cated that TGF-β1 increases stem cell function and
EMT in the CD44+/CD24- subpopulation of MDA-
MB231 breast cancer cells. In addition, we also found
that TGF-β1 increased the expression of GSN in the
CD44+/CD24- MDA-MB231 cells (Fig. 5d).
TGF-β1 induced epigenetic regulation of GSN gene
expressions in the CD44+/CD24- subpopulation of
MDA-MB231 cells
Alterations in GSN RNA expression in most breast can-
cers of rats, mice, and humans have been shown not due
to gross mutations of the GSN gene [30]. Alternately,
another route to modulate GSN expression is via epigen-
etic modification on GSN gene promotor [32–34]. To
test whether the TGF-β1 causes the epigenetic modifica-
tion on GSN expression in breast cancer cells, the
method of methylation-specific PCR (MSPCR) for asses-
sing the methylation and unmethylation on the CpG is-
land at the promoter region of GSN (intron 1) was used
in MDA-MB231 cells without FACS sorting (control), in
Fig. 3 Effects of GSN op on changes of cell morphology, cell surface elasticity, cytoskeletal protein expression, cell detachment, and migration in
MDA-MB231 breast cancer cells. a GSN op altered cell morphology and (b) increased cell surface elasticity in MDA-MB231 cells. Four different stable
GSN transfected MDA-MB231 cell clones were used. The calibration bar is 200 μm. Atomic force microscopy was applied to obtain with quantitative
analysis of the cell-surface adhesion force in control and GSN op MDA-MB231 cells. c Effect of GSN op on cell detachment for MCF-7 cells. d Effect of
GSN op on the protein levels shown by immunoblotting (top) with quantitative analyses (bottom) for caldesmon (CaD), tropomyosin 1 (Tm 1), GSN
and profilin (Pro) in MDA-MB231 cells. β-actin used as an internal control. e Effect of siTm 1 on cell detachment for MDA-MB231cells with or without
GSN op. f Effect of GSN on the cell migration in MDA-MB 231 cells. In b, c, d, e, f, the values are the mean ± SEM (n = 40 in b, n = 6 in c, d, e, f), with *,
# indicating a significant difference compared to the cells in control and GSNop-siTm, respectively
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CD44+/CD22- subpopulation sorted cells without TGF-
β1 pretreatment, and in CD44+/CD22- subpopulation
sorted cells with 2 ng/ml TGF-β1 pretreatment for 3 days
(Fig. 6a). In control MDA-MB231 cells without TGF-β1
stimulation, CD44+/CD22- subpopulation sorting cells in-
creased methylation by 10 folds but decreased unmethyla-
tion by 68 %. Interestingly, TGF-β1 pretreatment reduced
48 % methylation but increased 4 fold unmethylation of
GSN promotor in the CD44+/CD22- subpopulation
sorted cells (Fig. 6a). Consistently, two major DNA meth-
yltransferases, DNMT 1 and DNMT 3B, were found to
decrease their expression by 45 and 49 %, respectively,
with TGF-β1 pretreatment in the CD44+/CD22 subpopu-
lation sorted MDA-MB231 cells (Fig. 6b).
Discussion
A subpopulation of cancer stem cells (CSCs) within het-
erogeneous metastatic breast tumors have the ability to
differentiate into all the different cells found within a
tumor and they have stem cell characteristics, including
self-renewal, pluripotency, motility, tumor recurrence, and
Fig. 4 Effects of GSN op and/or silencing by small interfering RNA
on the expression of vimentin in MDA-MB231 breast cancer cells.
a Western blotting (top) with quantitative analyses (bottom) of GSN,
and vimentin, levels in control MDA-MB231 cells (Ctr), and GSN op
MDA-MB231cells treated with and/ or without siRNA against GSN
(siR) or lipofemitamine (Lipo). b Effect of siGSN on the protein content
of vimentin, and GSN in MDA-MB231 cells (Ctr). GAPDH used as an
internal control. In a and b, the values are the mean ± SEM (n = 3), with
*, # indicating a significant difference compared to the control cells
and Lipo-treated cells, respectively
Fig. 5 TGF-β1 induction increases the CD44+/CD24- subpopulation by coordinating gene expressions for CSC markers, EMT markers, and GSN in
MDA-MB231 cells. a Fluorescence-activated cell sorting (FACS) analysis to measure CD44 and CD24 expression for MDA-MB231 cells with (right) or
without (middle) additions of 2 ng/ml TGF-β1 for 3 days. CD44 and CD24 were detected by a combination of fluorochrome conjugated monoclonal
antibodies against human CD44 (APC) and CD24 (PE), respectively. Mock (left) used as unstained control MDA-MB231 cells without TGF-β1.
Data acquisition as shown below for each plot analysis. Real-time quantitative PCR (qPCR) analysis showing the increased gene expression for
markers, including (b) stem cell pluripotency (i.e. Oct4, Sox2 and Nanog), (c) mesenchymal cell markers such as N-cadherin, vimentin, and
E-cadherin, and for (d) GSN in post-sort CD44+/CD24- sub-population of MDA-MB231 cells with additions of 2 ng/ml TGF-β1 for 3 days. In
b, c, and d, each value is the mean ± SEM (n = 6). *indicates significant difference compared to mock control, and # symbolizes a significant
difference compared to post-sort CD44+/CD24- sub-population of MDA-MB231 cells without TGF-β1 treatment
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chemotherapy-resistance [35–37]. By sorting a subpopula-
tion of CD44+/CD24-(low) cells from human breast can-
cer tissue, Al-Hajj et al. were the first to demonstrate that
these cells can be enriched for breast CSCs and to develop
a tumor in immune-deficient mice [18]. In addition, TGF-
β has been shown to increase CSC numbers by producing
gene markers linked to stem cell function and Epithelial
to Mesenchymal Transition (EMT) in breast cancers [6].
More recently, evidence also showed that TGF-β could in-
crease breast CSCs in the low claudin subtype of breast
tumors [5]. In this study, we verified that with TGF-β1
treatment for 3 days the gene expression for CD44 and
GSN was increased in MDA-MB231 cells (Fig. 1) with in-
creasing the gene expression of EMT markers (Fig. 1) for
enhancing their cell migration and invasion. Our study
with FACS-flow cytometry also confirmed that TGF-β1
induction increased the CD44+/CD24- subpopulation of
MDA-MB231 cells (Fig. 5a). In the TGF-β1 enriched
CD44+/CD24- cells the mRNA expression levels for the
markers of stem cell pluripotency (i.e. Oct4, Sox2 and
Nanog) (Fig. 5b) were found to be increased in concomi-
tance with the increased expression for mesenchymal cell
markers (i.e. N-cadherin, Vimentin) but the decreased ex-
pression for epithelial cell marker (i.e. E-cadherin) (Fig. 5c).
It is of note that the GSN expression level is higher for the
TGF-β1 induction than for without TGF-β1 treatment
(Fig. 5d) in the CD44+/CD24- subpopulation of MDA-
MB231 cells. To test whether GSN plays a role in control-
ling cell proliferation and motility, we conducted GSN
overexpression (GSN op) in the two human breast cancer
cell lines of MDA-MB231 and MCF-7 (Figs. 2, 3). The re-
sults showed that GSN op altered cell morphology (Fig. 2)
and increased cell surface elasticity with an increase in cell
detachment, by which cause to increase the cell migra-
tion/invasion (Fig. 3). In addition, we also verified that
GSN plays a role in the gene expression for the mesenchy-
mal cell marker, vimentin in breast cancer cells with GSN
op and/or siGSN approaches (Fig. 4). Taken together, the
present study suggested that the modification of GSN ex-
pression might involve in the TGF-β1 signaling events for
inducing cancer cell stemness and increasing cell migra-
tion and invasion in CD44+/CD24- subpopulation of
breast cancer cells.
The regulation of GSN expression is varied in many
different tumors [38–44]. In oral cancers, biphasic ex-
pression of GSN was found during the progression of
carcinogenesis [40, 41]. Decreased GSN expression has
been found in many transformed and malignant cancer
cells, including breast cancers [42–44]. Evidence indi-
cated that GSN gene loss is one of the most common
disorders in invasive and metastatic breast cancers [45,
46]. Studies have shown that 71 % of human sporadic,
invasive breast carcinomas and 56 % of ductal carcin-
omas in situ were strikingly deficient in the GSN protein
[45, 46]. The clinical evidence also indicated that the
GSN expression may be associated with survival from
malignant breast cancers, and the frequency of GSN de-
ficiency increases significantly with progression to inva-
sive phenotypic cancer cells [45]. Recent studies have
found the increased GSN expressions in chemo-resistant
head and-neck (HNC) [47] and gynecological cancers
[48]. These studies suggested that GSN might play im-
portant roles for chemoresistance in cancers. Interest-
ingly, the present study showed that increased GSN
expression is associated with the TGF-β1 signaling for
breast CSC differentiation. Different cell populations of
breast cancer cells vary their GSN expression in re-
sponse to TGF-β1 induction (Fig. 5d). Only CSC-like
cells (i.e. CD44+/CD24-) in breast cancer cells respond
Fig. 6 TGF-β1 induced epigenetic regulation of GSN gene expressions
in the CD44+/CD24- subpopulation of MDA-MB231 cells. a Methylation
specific PCR (MSPCR) analysis showed epigenetic regulation of GSN
gene expression in the CD44+/CD24- subpopulation in MDA-MB-231
cells after TGF-β1 induction. b Real-time quantitative PCR analysis
showed decreases of gene expression of two DNA methyltrasferase,
DNMT1 and DNMT3B, in the CD44+/CD24- MDA-MB-231 cells
subpopulation after TGF-β1 induction. The values are the means ± SEM
(n = 6), with * indicating significant difference compared to mock control,
and # symbolizing a significant difference compared to post-sort
CD44+/CD24- sub-population of MDA-MB231 cells without
TGF-β1 treatment
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to TGF-β1 induction for increasing in GSN expression
such as to maintain their invasive phenotype. It will be of
interest to verify whether the TGF-β1 modified GSN ex-
pression is involved in chemoresistance in breast cancers.
Evidence showed that the GSN down-regulation is due to
decreased activity of the GSN promoter by activating tran-
scription factor-1 [49]. It was suggested that GSN expres-
sion and function can be further influenced by epigenetic
changes [16]. Epigenetic modulation involves modifications
of the transcriptional activation of certain genes [33, 34]. In
the present study, we showed that the CpG island methyla-
tion of the GSN gene was decreased in CD44+/CD24-
population of MDA-MB231 cells after TGF-β1 induc-
tion as compared to cells without treatment (Fig. 6a).
Accordingly, TGF-β1 increased GSN gene expression
in CD44+/CD24- population through decreases of
DNA methylation of CpG island at GSN promotor by in-
hibition of two major DNA methyltransferase, DNMT1
and DNMT3B. These two DNA methyltransferase were
decreased in the CD44+/CD24- subpopulation of MDA-
MB231 cells after TGF-β1 treatment (Fig. 6b). Apparently,
TGF-β1 induction attenuated the methylation but facili-
tated the unmethylation on GSN promoter region in
breast cancer cells such as to remove the inhibition on
GSN gene expression in MDA-MB231 cancer cells. Such
information on the relationship between TGF-β1 and its
control on DNA methyltransferase-dependent gene ex-
pression may have an important impact on the clinical
therapy of patients with metastatic breast cancers.
Conclusion
Our results suggested that TGF-β1 acting by epigenetic
modulation of GSN gene expression might be linked to the
signalling events for breast cancer stem cell differentiation.
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